Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position
RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements,…